INT116848

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2004
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 10
Total Number 20
Disease Relevance 19.68
Pain Relevance 1.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Chdh) oxidoreductase activity (Chdh)
Anatomy Link Frequency
blood 2
Chdh (Mus musculus)
Pain Link Frequency Relevance Heat
headache 30 100.00 Very High Very High Very High
adenocard 12 97.00 Very High Very High Very High
antagonist 44 80.00 Quite High
noradrenaline 7 75.00 Quite High
agonist 275 71.12 Quite High
Bile 55 63.68 Quite High
Botox 2 50.00 Quite Low
anesthesia 1 25.00 Low Low
tolerance 33 20.00 Low Low
Inflammation 121 13.08 Low Low
Disease Link Frequency Relevance Heat
Coronary Heart Disease 770 100.00 Very High Very High Very High
Coronary Artery Disease 177 100.00 Very High Very High Very High
Headache Disorders 23 100.00 Very High Very High Very High
Disorder Of Lipid Metabolism 3314 99.90 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

101 99.90 Very High Very High Very High
Atherosclerosis 634 98.00 Very High Very High Very High
Cancer 22 96.32 Very High Very High Very High
Nicotine Addiction 37 94.36 High High
Hypoalphalipoproteinemias 176 93.36 High High
Diabetes Mellitus 146 91.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The purpose of this article is to understand the CDH classification; determine the prevalence and associated demographic profile of CDH as derived from population-based studies; outline identified risk factors for development or persistence of CDH; and understand which risk factors may be more amenable to intervention.
Negative_regulation (persistence) of CDH associated with headache
1) Confidence 0.42 Published 2009 Journal Curr Pain Headache Rep Section Abstract Doc Link 19126373 Disease Relevance 0.70 Pain Relevance 0.70
CONCLUSIONS: The prevalence of CDH is greater among a primary care patient population compared to the general community.
Negative_regulation (prevalence) of CDH
2) Confidence 0.42 Published 2007 Journal Headache Section Body Doc Link 17355488 Disease Relevance 0.05 Pain Relevance 0
The prevalence of CDH among patients seen in the primary care setting in the United States, however, is unknown.
Negative_regulation (prevalence) of CDH associated with headache
3) Confidence 0.42 Published 2007 Journal Headache Section Abstract Doc Link 17355488 Disease Relevance 0.44 Pain Relevance 0.44
BACKGROUND: Population-based surveys estimate the prevalence of chronic daily headache (CDH) in the general community to be approximately 4%.
Negative_regulation (prevalence) of CDH associated with headache disorders and headache
4) Confidence 0.42 Published 2007 Journal Headache Section Abstract Doc Link 17355488 Disease Relevance 0.35 Pain Relevance 0.45
A forskolin derivative, colforsin daropate hydrochloride (CDH), acts directly on adenylate cyclase to increase the intracellular cyclic adenosine monophosphate levels which produce a positive inotropic effect and a lower blood pressure.
Negative_regulation (derivative) of CDH in blood associated with adenocard
5) Confidence 0.16 Published 2004 Journal Nephron Physiol Section Abstract Doc Link 14988663 Disease Relevance 0.06 Pain Relevance 0.15
Independent predictors for CDH persistence were medication overuse and major depression.
Negative_regulation (persistence) of CDH
6) Confidence 0.09 Published 2007 Journal Neurology Section Body Doc Link 17182975 Disease Relevance 0 Pain Relevance 0
Thus although it is clear that there are a number of different PON1 phenotypes and therefore possible that there is a phenotype which decreases CHD risk and leads to the null or weak findings we present here.
Negative_regulation (decreases) of CHD associated with coronary artery disease
7) Confidence 0.09 Published 2004 Journal BMC Genet Section Body Doc Link PMC449704 Disease Relevance 0.70 Pain Relevance 0
However, our own findings do not suggest that the PON1 R allele is associated with phenotypes that would reduce CHD risk, and the unexpected association with increased systolic blood pressure would increase CHD risk.
Negative_regulation (reduce) of CHD in blood associated with coronary artery disease
8) Confidence 0.09 Published 2004 Journal BMC Genet Section Body Doc Link PMC449704 Disease Relevance 0.86 Pain Relevance 0
Attempts to raise HDL are becoming increasingly frequent in the literature and most agree that raising HDL should be one of the goals in the management of atherogenic dyslipidemias for CHD risk reduction.
Negative_regulation (reduction) of CHD associated with coronary heart disease and disorder of lipid metabolism
9) Confidence 0.05 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.27 Pain Relevance 0.13
According to the guidelines, niacin is the preferred agent for use in combination with statins because of the availability of greater evidence for CHD event reduction with niacin compared with fibrates.26

General management of low HDL

Negative_regulation (reduction) of CHD associated with coronary heart disease and disorder of lipid metabolism
10) Confidence 0.05 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.61 Pain Relevance 0
This analysis, again, suggests that a focus exclusively on LDL reduction falls short of best possible CHD risk reduction.
Spec (possible) Negative_regulation (reduction) of CHD associated with coronary heart disease
11) Confidence 0.05 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.62 Pain Relevance 0
However, the CETP deficiency is not always predictably associated with decreased CHD risk.
Negative_regulation (decreased) of CHD associated with coronary heart disease
12) Confidence 0.05 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.17 Pain Relevance 0
Combination therapy and CHD risk reduction: summary
Negative_regulation (reduction) of CHD associated with coronary heart disease
13) Confidence 0.05 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.83 Pain Relevance 0
CONCLUSION: Simplified subcutaneous infiltration of TBA is very effective, convenient, fast and safe as a means of preventing CDH.


Negative_regulation (preventing) of CDH
14) Confidence 0.05 Published 2007 Journal Rev Neurol Section Body Doc Link 17918102 Disease Relevance 0 Pain Relevance 0
In the latest report, the NCEP ATP-III guidelines clearly indicate that low HDL is a significant and independent risk factor for CHD.6 The relationship is inversely proportional, such that 1 mg/dL rise in HDL imparts 2% to 3% reduction in CHD risk.7 Low HDL is frequently associated with high triglycerides and remnant lipoprotein levels.
Negative_regulation (reduction) of CHD associated with coronary heart disease and disorder of lipid metabolism
15) Confidence 0.04 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 2.18 Pain Relevance 0
HDL is a significant, independent risk factor that has been suggested as the next therapeutic target for reducing residual CHD risk.
Negative_regulation (reducing) of CHD associated with coronary heart disease and disorder of lipid metabolism
16) Confidence 0.04 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.43 Pain Relevance 0.07
For apo A-1 and apo B, there was a protective/inverse relationship with risk for a major CHD event when HDL was over 70 mg/dL in the IDEAL study.
Negative_regulation (event) of CHD associated with coronary heart disease and disorder of lipid metabolism
17) Confidence 0.04 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.72 Pain Relevance 0
For HDL, the ATP III report states ‘Low HDL cholesterol is a strong independent predictor of CHD’.
Negative_regulation (predictor) of CHD associated with coronary heart disease and disorder of lipid metabolism
18) Confidence 0.04 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.99 Pain Relevance 0
The panel stated that although clinical trial results suggest that raising HDL may reduce CHD risk, the evidence is yet insufficient to specify a target level of therapy.
Spec (may) Negative_regulation (reduce) of CHD associated with coronary heart disease and disorder of lipid metabolism
19) Confidence 0.04 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.69 Pain Relevance 0
Compared with the placebo group, the niacin group experienced an 11% reduction in total mortality and 12% reduction in CHD mortality (P = 0.0004 and P < 0.05, respectively.36 These findings suggest that treatment with niacin increased survival and the benefit was maintained even after stopping the therapy.


Negative_regulation (reduction) of CHD associated with coronary heart disease
20) Confidence 0.04 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.61 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox